InVitria Sponsors ESACT 2009 in Dublin, IrelandInVitria, a leading supplier of performance enhancing cell culture media supplements, to sponsor the 21st Meeting of the European Society for Animal Cell Technology (ESACT) in Dublin, Ireland from June 7-10, 2009. Fort Collins, CO June 4, 2009 - The world-renowned ESACT ‘09 gathering will serve as host to scientific experts from academia and industry brought together to find "Cellular Solutions for Clinical Challenges." As one of the sponsors, InVitria will be sharing with attendees the powerful effects of its portfolio of cell culture media supplements developed to solve the regulatory and performance challenges facing the life science industry. InVitria recently introduced a new product called ZAP-CHO, a performance enhancing cell culture media supplement designed to improve cell growth and antibody production in mammalian cell culture. "ZAP-CHO improves CHO product development in chemically defined media that are completely free of animal components," said Steve Pettit, Ph.D., Director of Cell Culture Development with InVitria. "Previously, the performance enhancements gained with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum or fetal calf serum) in cell culture media," said Dr. Pettit. Additionally, ZAP-CHO speeds-up cell line development and seed train expansion and also offers cost saving benefits by reducing operating costs as well as capital investment. Recent publications, along with customer results has validated that another of InVitria's leading cell culture supplements, Cellastim, a recombinant human serum albumin, outperforms other forms of albumin for growth and productivity. Cellastim is a key component in stem cell media and is used to safely optimize performance in CHO and hybridoma cell lines. "ESACT is a tremendous venue to build awareness of InVitria's product portfolio and collaborate with leaders in cellular biology," said Scott Deeter, InVitria President and CEO. "InVitria's products provide a unique opportunity for the cellular products industry to advance to a higher level of safety and productivity." About InVitria (www.InVitria.com) InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture products and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics. For more information about InVitria's performance enhancing reagents, contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
